Cue Biopharma

CUE62

Penny Stock

$1.09arrow_drop_up2.83%$0.03

Penny Stock

CUE62

$1.09

arrow_drop_up2.83%$0.03

Penny Stock

Performance History

Key Stats
Open	$1.05
Prev. Close	$1.06
EPS	-0.91
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$69.05M
PE Ratio	-

	LOW	HIGH
Day Range	1.03	1.13
52 Week Range	0.45	3.24

Ratios







EPS	-0.91

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Cue Biopharma (CUE)

Cue Biopharma Inc (CUE) is a biotechnology company that is focused on developing a novel class of injectable biologics to selectively engage and modulate targeted T cells within the human body. The company’s proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells), is designed to harness the body’s immune system to enable highly specific and controlled immune responses against disease. Cue Biopharma’s approach is based on the principle of redirecting the immune system to attack and eliminate diseased cells while sparing healthy cells. This targeted therapy has the potential to transform the treatment of a wide range of diseases, including various types of cancer and autoimmune disorders.

Cue Biopharma’s lead product candidate, CUE-101, is being developed for the treatment of HPV+ head and neck squamous cell carcinoma (HNSCC) and is currently in a phase 1 clinical trial. The company’s preclinical pipeline includes additional product candidates targeting solid tumors and infectious diseases. In addition to its internal programs, Cue Biopharma has collaborations with major pharmaceutical companies, including Merck and Bristol-Myers Squibb, to develop novel immunotherapies.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Daniel R. Passeri J.D., M.Sc., MSc.
Headquarters: Boston
Employees: 51
Exchange: NASDAQ

Keep an eye on Cue Biopharma

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Cue Biopharma 's (CUE) price per share?

The current price per share for Cue Biopharma (CUE) is $1.09. The stock has seen a price change of $0.03 recently, indicating a 2.83% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Cue Biopharma (CUE)?

For Cue Biopharma (CUE), the 52-week high is $3.25, which is 198.07% from the current price. The 52-week low is $0.45, the current price is 142.22% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Cue Biopharma (CUE) a growth stock?

Cue Biopharma (CUE) has shown an average price growth of -3.4% over the past three years. It has received a score of 2 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cue Biopharma as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Cue Biopharma (CUE) stock price performance year to date (YTD)?

As of the latest data, Cue Biopharma (CUE) has a year-to-date price change of -60.79%. Over the past month, the stock has experienced a price change of -38.76%. Over the last three months, the change has been 49.11%. Over the past six months, the figure is -32.72%. Looking at a longer horizon, the five-year price change stands at -90.01%.

help

Is Cue Biopharma (CUE) a profitable company?

Cue Biopharma (CUE) has a net income of -$50.73M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -390.63% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $5.49M, although specific revenue growth data is currently not available. Operating income is noted at -$52.15M. Furthermore, the EBITDA is -$47.71M.

help

What is the market capitalization of Cue Biopharma (CUE)?

Cue Biopharma (CUE) has a market capitalization of $69.05M. The average daily trading volume is 1.06, indicating the stock's liquidity and investor engagement.

News

CUE BIOPHARMA

PIPER SANDLER

HEALTHCARE CONFERENCE

CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY

IMMUNO-STAT

T CELLS

Nov 25, 2024

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Cue Biopharma Announces Strategic Organizational Transition

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Cue Biopharma Announces Proposed Public Offering